PRO-DNA Diagnostic is a dynamic company that offers a stimulating working environment where the desire to succeed is coupled with professional development opportunities and quality of life for its employees. Organized by activity groups, the company encourages teamwork and a co-operative approach to carrying out its everyday activities in which the contributions of each and every participant are valued. The recent construction of its new offices and laboratory offers a healthy working environment at a location that can be easily accessed by car and public transit. PRO-DNA Diagnostic is always looking for specialized personnel in the fields of biotechnology, molecular medicine, human identification testing, research and development, management and marketing. During its recruitment sessions, the company seeks to validate both the incumbent's expertise in the desired area of specialization and his or her versatility regarding the company's changing needs. Special attention is paid to the incumbent's ability to work as a team member and to contribute to multidisciplinary work teams. PRO-DNA Diagnostic subscribes to the principles of employment equity. Anyone interested in applying may do so on-line by completing the form below. You can also join our distribution list and receive our job postings by e-mail.
GenomeWeb LLC is an independent, privately-held online and print publisher based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research. GenomeWeb's editorial mission is to serve readers with exclusive, in-depth coverage of the technology, institutions, and scientists that make up the worldwide research enterprise of molecular biology. We operate the largest online news organization focused on advanced research tools in genomics, proteomics, and bioinformatics. Our expert editors report and write with precision and clarity. GenomeWeb comprises three parts: Genome Technology - the Genome Technology Online website and a monthly magazine with print and digital editions - reaches a global community of active scientists working in pharmaceutical and biotech companies, universities, and biomedical research institutions. Genome Technology Online is a free Web service supported by advertising. Genome Technology Magazine is a free journal for qualified subscribers and is supported by advertising. GenomeWeb Daily News is an opt-in online service edited in the GenomeWeb newsroom and providing twice-daily news updates on the technology, business, and science of molecular biology. GenomeWeb Daily News is a free service supported by advertising. Our nine Application-Focus Newsletters provide exclusive, behind-the-scenes news reports on specific research and technology areas, including microarrays, bioinformatics, pharmacogenomics, RNA interference, and proteomics. (Click here for detailed descriptions.) Application-Focus Newsletters are paid-subscription services. GenomeWeb users can be found in major scientific organizations around the world, including biopharmaceutical companies, important research universities, biomedical institutes, and government laboratories. Our advertisers include leading suppliers of research tools, analytical instruments, and information technology.
GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of ‘next generation' protein products for already-developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins.
DxS is a personalised medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. DxS offers products, technology and services to the healthcare industry to enable the delivery of safe and effective medicines. Working predominantly in the field of cancer, DxS have a range of companion diagnostic and research kits that detect mutations in oncogenes associated with cancer drug response. The TheraScreen® range of CE-marked diagnostic products includes kits that detect mutations in the EGFR and K-RAS genes. Tumour mutation products are available for research use for EGFR, RAS, RAF, BCR-ABL and other genes that show a correlation between patient mutation status and drug response. DxS' real-time PCR technology Scorpions®, known for its speed and sensitivity, underpins the products and services offered by DxS. This class-leading technology is also available for licence to diagnostic companies, for research, applied and other applications. DxS also provide a genetic analysis service to support clinical development. DxS is ISO 13485: 2003 and ISO 9001: 2000 certified for the manufacture of medical devices and the provision of genetic analysis services and technologies to the healthcare industry. DxS is an established company operating in Manchester's Technology Quarter within the UK.
OpGen offers its whole genome mapping technology on a fee-for-service, or collaborative basis. Send your DNA samples to OpGen (see Submitting Samples, below) for analysis. You will receive the whole-genome map(s), relevant analyses performed using OpGen's proprietary informatics tools, and software to utilize the map data in your genomics program.
About Inpharmatica: (http://www.inpharmatica.com) Founded in 1998, Inpharmatica Ltd is a selective drug discovery company using predictive technologies to improve speed and productivity. Focusing on highly druggable targets, its unique proprietary platform, PharmaCarta (TM), is an integrated suite of informatics-based technologies fully capable of rapid gene to candidate operations. Inpharmatica's lead discovery programme is focused on generating pre-clinical candidates against 16 novel nuclear receptors - proteins widely considered to be both druggable and of high therapeutic interest. Other significant programmes include novel secreted proteins/antibody targets, ion channels, P450 enzymes, metalloproteinases and progestin receptors. The Company employs approximately 100 professionals at its UK locations in London and Cambridge, with business development headed in North America. Inpharmatica has raised some GBP35m from leading venture capitalists and has sales/collaboration partnerships with Serono, Pfizer, GSK, Aventis, P&G, Daiichi, Riken, Taisho, Chugai, MDL, Ionix, CellZome and Galapagos.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory